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Introduction
Although up to 80 % of patients with acute myeloid leukemia (AML) achieve first hematological complete remission (CR1) with current induction chemotherapy, a substantial number of patients have an individualized risk of relapse.(1) Several risk factors have been defined in CR1 and these are used to stratify the treatment strategy in CR1.(2-4) However, once they relapse, the probability of achieving a second complete remission (CR2) becomes less likely and the duration of the second disease-free interval is generally reported to be shorter, which mean that the prognosis of patients who relapse is still challenging. (5) (6) (7) (8) (9) (10) Several retrospective studies have tried to identify the prognostic factors and optimal treatment strategies after first relapse. 
Design and Methods

Patients
The study protocol was approved by the Institutional Review Board at National Cancer Center Hospital. We constructed a new database of adult patients, aged 16 to 70 years, who were diagnosed with AML according to the WHO classification between 1999 and 2006, and who had achieved CR1 after 1 or 2 courses of induction chemotherapy. Clinical information on over 2,500 patients was collected from 70 institutions across the country. Among them, patients with biphenotypic leukemia who were treated with chemotherapy for acute lymphocytic leukemia and those who had extramedullar AML without marrow invasion, an extramedullar lesion that did not totally disappear after remission induction chemotherapy or acute promyelocytic leukemia were excluded from the analysis. As patients who relapsed after treatment with conventional chemotherapy alone were analyzed in this study, those who received autologous HCT in CR1 were also excluded.
Statistical analysis
Data were retrospectively reviewed and analyzed as of February 2010.
Background differences between 2 groups were examined with the chi-square test for categorical variables and the t-test for continuous variables. The primary endpoint of the study was overall survival (OS) after first relapse. OS from CR1, OS and cumulative incidences of relapse and non-relapse mortality (NRM) from the date of allo-HCT were also estimated. The unadjusted probabilities of OS were estimated using the Kaplan-Meier product limit method, and 95% confidence intervals (CIs) were calculated using the Greenwood formula. To compare OS among different subgroups, the log-rank test was used. The Pepe-Mori test was used to evaluate differences in the cumulative incidence among groups. OS and incidences of relapse and NRM were estimated as probabilities at 3 years from the time of the first relapse, allo-HCT or CR1. Cox proportional hazard regression model was used to estimate relative hazard ratios for OS, and risk ratio regression model was used to estimate risk ratios for the achievement of CR2. The following factors were considered as covariates: age, RFI from CR1, achievement of CR2, application of salvage allo-HCT, number of courses of chemotherapy required to achieve CR1, cytogenetic risks according to SWOG,(4) French-American-British (FAB) cytologic classification, WBC count, and dysplasia at diagnosis. We considered two-sided P-values of <0.05 to be statistically significant. Statistical analyses were performed with the SPSS software package and SAS version 9.1.3 (SAS, Cary, NC, USA).
Results
Patients
Among the 2,029 AML patients who achieved CR1, 494 patients received allo-HCT in CR1. The remaining 1,535 patients were treated with conventional chemotherapy alone, and 1,015 subsequently relapsed at a median interval of 8.8
months from CR1 (range, 0.3-98.7 months, Figure 1 ). The median age of those who relapsed was 53 years (range, 16-70 years), and the median follow-up of patients who relapsed was 49 months (range, 5-116 months). As shown in Table 1 , there were significant differences in clinical characteristics between patients who received allo-HCT in CR1 and those who did not, and between patients who relapsed after being treated with chemotherapy alone and those who did not. As a remission induction therapy, 87% of 2,029 patients had received cytarabine-and anthracycline (daunorubicin or idarubicin) -based regimen. The remaining patients were treated with low dose araC-based regimens (5%), BHAC-based regimens (5%), or others (3%). Consolidation therapy was also continued with cytarabine-based regimens with or without maintenance therapy. After first relapse, most of patients received cytarabine + anthracycline-based re-induction chemotherapy at the discretion of physicians.
Outcome after first relapse
The OS of the 1,015 patients who relapsed was 30% at 3 years after first relapse (Figure 2A ). OS after relapse was significantly affected by age, RFI from CR1, the number of courses of chemotherapy required to achieve CR1 and cytogenetic classification ( Figure 2B-E) .
Salvage Allo-HCT after First Relapse
Among 931 patients for whom detailed information after relapse was available, 463 achieved CR2 (50%, Figure 1) allo-HCT, and 242 (80%) of them received HCT while remaining in CR2. On the other hand, 189 (40%) of the 468 patients who did not achieve CR2 received salvage allo-HCT in non-remission status. Overall, half of the patients received salvage allo-HCT after their first relapse and showed an improved OS compared to patients who survived at least 2 months after relapse and did not receive allo-HCT (44% vs 14% at 3 years from the first relapse, p<0.001, Figure 2F ).
Comparison of disease status at Allo-HCT
We compared the outcome after salvage allo-HCT to that after allo-HCT in CR1. As shown in Table 1 , 527 patients who received allo-HCT after relapse were less frequently associated with unfavorable factors compared to 494 patients who received allo-HCT in CR1. Donor sources for salvage HCT were HLA-matched related (31%), 1-antigen mismatched related (6%), unrelated bone marrow (40%), or unrelated cord blood (24%). The conditioning regimens were myeloablative (65%, median age: 37 years) or reduced-intensity (35%, median age: 55 years) regimens (Appendix 1). An unrelated donor, especially unrelated cord blood, was more frequently used and there was a slight increase in the use of a reducedintensity conditioning regimen in allo-HCT after relapse. OS was significantly better in allo-HCT in CR1 than after relapse (67% vs 51% at 3 years from CR1, p<0.001, Figure 3A ). This result did not change when patients who relapsed within 2 months from CR1 were excluded from among those who received allo-HCT after relapse. The statistical difference between the outcomes of the two groups also remained whether the donor was matched related or not.
When OS was compared in terms of the disease status at allo-HCT after relapse, patients who received allo-HCT in CR2 had a significantly better OS than those who achieved CR2 but subsequently relapsed by the time of allo-HCT and those who never achieved CR2 (59%, 29%, and 21% at 3 years from HCT, p<0.001, Figure 3B ). This result led us to compare the outcomes of allo-HCT in CR1 and CR2. There was no significant difference in terms of OS, NRM or relapse after allo-HCT between the two groups (OS, 64% vs 59%, p=0.090; NRM, 18% vs 20%, p=0.316; relapse, 22% vs 27%, p=0.061, Figure 3C , E, and F). The OS was also compared from CR1, and the survival curves were almost superimposable (67% vs 68%, p=0.629, Figure 3D ).
Treatment strategy after first relapse
We also investigated the outcomes with or without subsequent allo-HCT after the achievement of CR2 and the effectiveness of allo-HCT when CR2 was not achieved or sustained (Figure 4) . We divided the 1015 patients who relapsed into four groups according to the cytogenetic risks: inv (16) Figure 4A ). For patients with t(8;21), OS probabilities were generally inferior compared to those with inv(16) (allo-HCT in CR2, 64%; no allo-HCT after CR2, 53%; allo-HCT in non-CR2, 32%; no achievement of CR2 without salvage allo-HCT, 0%, Figure 4B ). Also in this group of patients, there was no significant difference in OS between allo-HCT in CR2 and no allo-HCT after CR2 (p=0.600).
Allo-HCT in a disease status other than CR2 provided significantly better survival than no achievement of CR2 without salvage allo-HCT (p<0.001).
Among patients with intermediate-risk AML, OS in those who did not receive allo-HCT after they achieved CR2 was significantly worse than that in patients who did receive allo-HCT in CR2 (58% vs 19% at 3 years from relapse, p<0.001, Figure 4C ). We performed subset analyses according to RFI (! 1 year vs < 1 year) and the number of courses of remission induction therapy (1 course or 2 courses) among intermediate-risk patients. The performance of allo-HCT in CR2 was associated with significantly better OS than no allo-HCT after the achievement of CR2 or allo-HCT in a disease status other than CR2 in all subgroups other than those who required 2 courses of remission induction chemotherapy (Appendices 2C-F). Allo-HCT in non-CR2 provided a comparable or better OS than no allo-HCT after CR2, and a significantly better OS than no remission/no allo-HCT.
Among patients with unfavorable-risk AML, only selected patients who received allo-HCT in CR2 had an improved OS (allo-HCT in CR2, 67%; no allo-HCT after CR2, 35%; allo-HCT in non-CR2, 13%; no achievement of CR2 without salvage allo-HCT, 0%, Figure 4D ).
Prognostic factors after first relapse
A multivariate analysis showed that the achievement of CR2, salvage allo-HCT, a longer RFI from CR1, a more favorable cytogenetic risk and a single course of induction therapy to achieve CR1 were significantly associated with improved OS after relapse (Table 2) . Since CR2 was shown to be an important step toward an improved prognosis after the first relapse, we also performed a multivariate analysis to identify factors that may be associated with the likelihood of the achievement of CR2.
Except for age, these already-known prognostic factors were found to independently predict the achievement of CR2 with a relatively higher risk ratio in RFI.
Discussion
In this study, we investigated the prognosis of 1,015 patients who relapsed after being treated with conventional chemotherapy during CR1. The independent prognostic factors we identified were achievement of CR2, performance of salvage allo-HCT, a RFI 1 year or longer, a more favorable cytogenetic risk and achievement of CR1 after a single course of remission induction chemotherapy. Although the outcomes of allo-HCT after a first relapse were inferior to that in CR1, we found that a comparable outcome was achieved when allo-HCT was successfully performed in CR2. We also found that the outcome according to the treatment strategy after the first relapse varied depending upon the cytogenetic risks.
Overall, the OS of the 1,015 relapsed patients was 30% at 3 years from the first relapse. The OS significantly differed according to factors that have been reported to be prognostic factors at diagnosis or after relapse. Breems et al. presented a prognostic score to predict the outcome of AML after first relapse, including patients who relapsed after allo-HCT in CR1.(12) They indicated that a longer RFI, a favorable cytogenetic risk, and a younger age were favorable prognostic factors and that the performance of allo-HCT before first relapse unfavorably influenced the outcome after relapse.
Armistead et al. showed that allo-HCT was effective in patients with refractory or recurrent AML who were stratified into diverse subgroups according to age, RFI and cytogenetics.(11) In our study, achievement of CR2, performance of salvage allo-HCT, a longer RFI, a more favorable cytogenetic risk and achievement of CR1 after a single course of remission induction chemotherapy were independent prognostic factors in patients who relapsed after conventional chemotherapy. Our database only consisted of patients who successfully achieved CR1 and subsequently relapsed after treatment with chemotherapy alone, which may be one of the reasons why we found slightly different prognostic factors from these prior studies. Salvage chemotherapy yielded CR2 in half of the patients, which was consistent with the previously reported probability. (5) We found that, overall, allo-HCT after first relapse provides an inferior OS compared to allo-HCT in CR1. This result did not change when we excluded patients who relapsed early after they had achieved CR1. The outcome after salvage allo-HCT was significantly affected by the disease status at transplantation. Patients who received salvage allo-HCT in a disease state other than CR2 had a significantly worse OS than those who received allo-HCT in CR2. Patients who never achieved CR2 may include not only those who received chemotherapy but also those who never received chemotherapy after relapse. Nevertheless, our results may indicate that an immediate salvage allo-HCT after relapse without an effort to induce CR2 by giving remission induction chemotherapy did not improve the prognosis.
Achievement of CR2 was shown to be a crucial step for an improved outcome after relapse. Additionally, one of the intriguing facts we found was that patients who received allo-HCT in CR2 had an OS that was comparable to that in patients who received allo-HCT in CR1. For patients who do not have a definite indication for allo-HCT in CR1, the likelihood of successfully receiving allo-HCT in CR2 if they relapsed would be invaluable information. However, among the available prognostic factors that are generally used to predict the ultimate prognosis of AML at diagnosis, all of the factors except for age were shown to be independent factors that predicted the achievement of CR2. As a result, it was difficult to clearly define candidates for allo-HCT, not in CR1, but rather in CR2 using already-known prognostic factors.
These results may suggest the need for further information on how parameters such as WT-1 or other molecular markers behave in AML after relapse.
We also investigated the advantage of additional allo-HCT after the achievement of CR2 as well as the effectiveness of allo-HCT if CR2 was not achieved or sustained.
The outcomes were analyzed based on stratification according to cytogenetic risks.
We found that patients with core-binding factor (CBF) AML who did not receive additional allo-HCT after they had achieved CR2 had an outcome that was comparable to that in patients who received allo-HCT in CR2. Over 80% of the patients with inv (16) Among patients with unfavorable-risk AML, only one third achieved CR2.
Although allo-HCT in CR2 provided an improved outcome after relapse, the probability to successfully receive HCT in CR2 was only 15% of all the patients with unfavorable-risk AML who relapsed. Since survival is less likely after the first relapse, patients with unfavorable-risk AML should promptly prepare for allo-HCT in CR1, as has been demonstrated in many prior studies. (2, 4, (22) (23) (24) (25) Our results may be susceptible to the disadvantages of any retrospective study, such as the heterogeneity in the treatment strategies chosen at the discretion of physicians. The performance of allo-HCT after relapse may include several inherent selection biases such as unfavorable features in those who did not have a chance to receive allo-HCT because of disease progression or comorbidity. Our database also lacked detailed information on chemotherapy treatment after achievement of CR1 or after relapse. However, the results we obtained from this large database that consists of clinical information on patients who were treated with chemotherapy alone or salvage allo-HCT after relapse should provide valuable information on this issue that is difficult to evaluate in a prospective randomized manner.
In summary, by using a retrospectively collected large database, we showed that both the achievement of CR2 and the application of salvage allo-HCT after relapse are crucial factors in improving the outcome after first relapse. Our results also suggested that the optimal treatment strategy after relapse may differ based on the risk of the disease. Further studies on molecular profiles are needed to stratify the prognosis and treatment strategies of AML after first relapse. 
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